Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients

Antiviral Therapy

Volumn 11, Issue 1, 2006, Pages 47-51

  Molto, José ^a,c   Ruiz, Lidia ^a   Valle, Marta ^b,c   Martinez Picado, Javier ^a   Bonjoch, Ana ^a   Bravo, Isabel ^a   Negredo, Eugenia ^a   Heilek Sneider, Gabrielle M ^d   Clotet, Bonaventura ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d Roche   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; ENFUVIRTIDE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIREMIA; VIRUS LOAD;

ADENINE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; LAMIVUDINE; OXAZINES; PATIENT COMPLIANCE; PEPTIDE FRAGMENTS; PHOSPHONIC ACIDS; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME;

EID: 33644531929     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced huma immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
2. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999; 13:F35-F43.
3. Barlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antirretroviral-naive HIV-1 infected adults. AIDS 2001; 15:1369-1377.
4. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 1997; 387:188-191.
5. Easterbrook PJ, Newson R, Ives N, Pereira S, Moyle G, Gazzard BJ. Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens. J AIDS 2001; 27:350-364.
6. Weverling GJ, Lange J, Jurriaans S, et al. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS 1998; 12:F117-F122.
7. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271:1582-1586.
8. Perelson AS, Nelson PW. Mathematical analysis of HIV-1: dynamics in vivo. SIAM Rev 1999; 41:3-44.
9. Markowitz M, Louie M, Hurley A, et al. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol 2003; 77:5037-5038.
10. Louie M, Hogan C, Di Mascio M, et al. Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis 2003; 187:896-900.
11. Ho DD. Dynamics of HIV-1 replication in vivo. J Clin Invest 1997; 99:2565-2567.
12. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-2185.
13. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-2195.
14. Arastèh K, Lazzarin A, Clotet B, et al. TORO: 96-week virological and immunological response and safety evaluation of enfuvirtide with an optimized background regimen. 15th International AIDS Conference. 11-16 July 2004, Bangkok, Thailand. Abstract MoOrB1058.
15. Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [monograph on internet]. Rockville: AIDSinfo; 2005 [cited 2006 Jan 24]. Available from: http://aidsinfo.nih.gov/content-files/adultandadolescentGL.pdf
16. Wu H, Mellors J, Ruan P, Mc Mahon D, Keller D & Lederman MM. Viral dynamics and their relations to baseline factors and longer term virologic responses in treatment-naive HIV-1 infected patients receiving abacavir in combination with HIV-1 protease inhibitors. J AIDS 2003; 33:557-563.
17. Wu H, Kuritzkes DR, McClernon DR, et al. Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. J Infect Dis 1999; 179:799-807.
18. van Leth F, Huisamen CB, Badaro R, et al. Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy. J AIDS 2005; 38:296-300.
19. Polis MA, Sidorov IA, Yoder C, et al. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and long-term efficacy. Lancet 2001; 358:1760-1765.
20. Mittler J, Essunger P, Yuen GJ, Clendeninn N, Markowitz M, Perelson AS. Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy. Antimicrob Agents Chemother 2001; 45:1438-1443.